bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure S1 from Regular Glucosamine Use May Have Different Roles in the Risk of Site-Specific Cancers: Findings from a Large Prospective Cohort
Authors: Li Fu-Xiao , Zhao Hou-Yu , Lin Teng-Fei , Jiang Yi-Wen , Liu Di , Wei Chang , Zhao Zi-Yi , Yang Zu-Yao , Sha Feng , Yang Zhi-Rong , Tang Jin-Ling
Published: April 2023

Supplementary Figure S1 shows subgroup analyses for the association between glucosamine use and incidence of prostate cancer in male participants.
Data from Application of Novel Breast Biospecimen Cell-Type Adjustment Identifies Shared DNA Methylation Alterations in Breast Tissue and Milk with Breast Cancer–Risk Factors
Authors: Muse Meghan E. , Carroll Connolly D. , Salas Lucas A. , Karagas Margaret R. , Christensen Brock C.
Published: April 2023

AbstractBackground:
DNA methylation patterning is cell-type–specific and altered DNA methylation is well established to occur early in breast carcinogenesis, affecting non-cancerous, histopathologically normal breast tissue. Previous work assessing risk factor–associated alterations to DNA methylation in breast tissue has been limited, with even less published research in breast milk, a noninvasively obtained biospecimen containing sloughed mammary epithelial cells that may identify early alterations indicative of cancer risk.
Methods:
Here, we present a novel library for the estimation of the cellular composition of breast tissue and milk and subsequent assessment of cell-type–independent alterations to DNA methylation associated with established breast cancer–risk factors in solid breast tissue (n = 95) and breast milk (n = 48) samples using genome-scale DNA methylation measures from the Illumina HumanMethylation450 array.
Results:
We identified 772 hypermethylated CpGs (P < 0.01) associated with age consistent between breast tissue and breast milk samples. Age-associated hypermethylated CpG loci were significantly enriched for CpG island shore regions known to be important for regulating gene expression. Among the overlapping hypermethylated loci mapping to genes, a differentially methylated region was identified in the promoter region of SFRP2, a gene observed to undergo promoter hypermethylation in breast cancer.
Conclusions:
Our findings suggest the potential to identify epigenetic biomarkers of breast cancer risk in noninvasively obtained, tissue-specific breast milk specimens.
Impact:
This work demonstrates the potential of using breast milk as a noninvasive biomarker of breast cancer risk, improving our ability to detect early-stage disease and lowering the overall disease burden.
Data from Regular Glucosamine Use May Have Different Roles in the Risk of Site-Specific Cancers: Findings from a Large Prospective Cohort
Authors: Li Fu-Xiao , Zhao Hou-Yu , Lin Teng-Fei , Jiang Yi-Wen , Liu Di , Wei Chang , Zhao Zi-Yi , Yang Zu-Yao , Sha Feng , Yang Zhi-Rong , Tang Jin-Ling
Published: April 2023

AbstractBackground:
Previous studies indicated that glucosamine supplements may have a general anticancer effect. This study aimed to assess whether the potential effect differs across different types of cancers in a large prospective cohort study.
Methods:
All participants from the UK Biobank who were free of cancers and had complete information on glucosamine use at baseline were included and followed up from 2006 until 2021. Cox proportional hazards models were used to assess the associations between regular glucosamine use and different site-specific cancers. Subgroup analyses were performed to explore potential interactions. Several sensitivity analyses were conducted to assess the robustness of the main findings.
Results:
A total of 450,207 eligible participants (mean age: 56.2 years; females: 53.3%) were included, of whom 84,895 (18.9%) reported regular glucosamine use at baseline. During a median of 12.5 years follow-up, glucosamine use was significantly associated with an increased risk of overall cancer [HR, 1.04; 95% confidence interval (CI), 1.01–1.06], skin cancer (HR, 1.11; 95% CI, 1.07–1.15), and prostate cancer (HR, 1.07; 95% CI, 1.01–1.13), and with a reduced risk of lung cancer (HR, 0.88; 95% CI, 0.79–0.97) after adjusting for potential confounders. Statistical interaction was observed for gender, age, and education for the association of glucosamine use with overall cancer risk (all Pinteraction < 0.027). These results remained unchanged in the sensitivity analyses.
Conclusions:
Regular glucosamine use was associated with lower risk of lung cancer but higher risk of skin cancer, prostate cancer, and overall cancer.
Impact:
The roles of glucosamine use potentially differ in the development of different site-specific cancers.
Supplemental Table 2 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
Authors: Lapin Morten , Edland Karin H. , Tjensvoll Kjersti , Oltedal Satu , Austdal Marie , Garresori Herish , Rozenholc Yves , Gilje Bjørnar , Nordgård Oddmund
Published: April 2023

ctDNA point mutation variants in baseline samples
Supplemental Table 1 from Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer
Authors: Lapin Morten , Edland Karin H. , Tjensvoll Kjersti , Oltedal Satu , Austdal Marie , Garresori Herish , Rozenholc Yves , Gilje Bjørnar , Nordgård Oddmund
Published: April 2023

CHIP variants in cfDNA
Supplementary Table S5 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
Authors: Osman Abdullah A. , Arslan Emre , Bartels Mason , Michikawa Chieko , Lindemann Antje , Tomczak Katarzyna , Yu Wangjie , Sandulache Vlad , Ma Wencai , Shen Li , Wang Jing , Singh Anand K. , Frederick Mitchell J. , Spencer Nakia D. , Kovacs Jeffery , Heffernan Timothy , Symmans William F. , Rai Kunal , Myers Jeffrey N.
Published: April 2023

Supplementary Table S5A. Bulk-level single cell ATAC sequencing analysis showing immediate (short-term) chromatin openings (peaks) in HN30-P cells following CDDP treatment; Supplementary Table S5B. Bulk-level single cell ATAC sequencing analysis showing long-term chromatin openings (peaks) gained in cisplatin-resistant HN30-R8 cells following CDDP treatment.
Supplementary Materials and Methods S1 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
Authors: Osman Abdullah A. , Arslan Emre , Bartels Mason , Michikawa Chieko , Lindemann Antje , Tomczak Katarzyna , Yu Wangjie , Sandulache Vlad , Ma Wencai , Shen Li , Wang Jing , Singh Anand K. , Frederick Mitchell J. , Spencer Nakia D. , Kovacs Jeffery , Heffernan Timothy , Symmans William F. , Rai Kunal , Myers Jeffrey N.
Published: April 2023

Supplementary Materials and Methods
Supplementary Figure S9 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
Authors: Osman Abdullah A. , Arslan Emre , Bartels Mason , Michikawa Chieko , Lindemann Antje , Tomczak Katarzyna , Yu Wangjie , Sandulache Vlad , Ma Wencai , Shen Li , Wang Jing , Singh Anand K. , Frederick Mitchell J. , Spencer Nakia D. , Kovacs Jeffery , Heffernan Timothy , Symmans William F. , Rai Kunal , Myers Jeffrey N.
Published: April 2023

In vivo expression of cisplatin transporters in CDDP resistant HNSCC tumors.
Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
Authors: Patel Sonia A. , Nilsson Monique B. , Yang Yan , Le Xiuning , Tran Hai T. , Elamin Yasir Y. , Yu Xiaoxing , Zhang Fahao , Poteete Alissa , Ren Xiaoyang , Shen Li , Wang Jing , Moghaddam Seyed Javad , Cascone Tina , Curran Michael , Gibbons Don L. , Heymach John V.
Published: April 2023

EGFR-mutant NSCLC EGFR-independent tumor model is refractory to EGFR-TKI treatment.
Supplementary Figure S8 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
Authors: Osman Abdullah A. , Arslan Emre , Bartels Mason , Michikawa Chieko , Lindemann Antje , Tomczak Katarzyna , Yu Wangjie , Sandulache Vlad , Ma Wencai , Shen Li , Wang Jing , Singh Anand K. , Frederick Mitchell J. , Spencer Nakia D. , Kovacs Jeffery , Heffernan Timothy , Symmans William F. , Rai Kunal , Myers Jeffrey N.
Published: April 2023

IACS-6274 improves survival and is well tolerated in combination with cisplatin in mice.
Supplementary Figure S2 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
Authors: Patel Sonia A. , Nilsson Monique B. , Yang Yan , Le Xiuning , Tran Hai T. , Elamin Yasir Y. , Yu Xiaoxing , Zhang Fahao , Poteete Alissa , Ren Xiaoyang , Shen Li , Wang Jing , Moghaddam Seyed Javad , Cascone Tina , Curran Michael , Gibbons Don L. , Heymach John V.
Published: April 2023

Development of IL-6 knockout EGFR-mutant GEMM tumors.
Supplementary Figure S5 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
Authors: Osman Abdullah A. , Arslan Emre , Bartels Mason , Michikawa Chieko , Lindemann Antje , Tomczak Katarzyna , Yu Wangjie , Sandulache Vlad , Ma Wencai , Shen Li , Wang Jing , Singh Anand K. , Frederick Mitchell J. , Spencer Nakia D. , Kovacs Jeffery , Heffernan Timothy , Symmans William F. , Rai Kunal , Myers Jeffrey N.
Published: April 2023

NRF2 targeted suppression or restoration of wild type KEAP1 decreases distant metastasis in cisplatin resistant HNSCC cells.
Supplementary Figure S4 from Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma
Authors: Osman Abdullah A. , Arslan Emre , Bartels Mason , Michikawa Chieko , Lindemann Antje , Tomczak Katarzyna , Yu Wangjie , Sandulache Vlad , Ma Wencai , Shen Li , Wang Jing , Singh Anand K. , Frederick Mitchell J. , Spencer Nakia D. , Kovacs Jeffery , Heffernan Timothy , Symmans William F. , Rai Kunal , Myers Jeffrey N.
Published: April 2023

Restoration of wildtype KEAP1 improves survival in mice.
Supplementary Table S1 from Event-Free Survival as a Surrogate for Overall Survival in Gastric and Gastroesophageal Junction Adenocarcinoma: A Meta-analysis in the Neoadjuvant ± Adjuvant Setting
Authors: Wainberg Zev A. , Xie Jipan , Valderrama Adriana , Yin Lei , Zhang Shujing , Shih Chie-Schin , Bhagia Pooja , Gu Qianqian , Shitara Kohei , Janjigian Yelena Y. , Tabernero Josep
Published: April 2023

Summary of main study characteristics of the neoadjvuant RCTs included in the analyses
Supplementary fig 2 from Pathogenic Variants in Adult-Onset Cancer Predisposition Genes in Pediatric Cancer: Prevalence and Impact on Tumor Molecular Features and Clinical Management
Authors: McGee Rose B. , Oak Ninad , Harrison Lynn , Xu Ke , Nuccio Regina , Blake Alise K. , Mostafavi Roya , Lewis Sara , Taylor Leslie M. , Kubal Manish , Ouma Annastasia , Hines-Dowell Stacy J. , Cheng Cheng , Furtado Larissa V. , Nichols Kim E.
Published: April 2023

Supplementary Figure 2. Molecular features of tumors harboring pathogenic aoCPG variants showing the full range of additional somatic second hits.
Supplementary fig 1 from Pathogenic Variants in Adult-Onset Cancer Predisposition Genes in Pediatric Cancer: Prevalence and Impact on Tumor Molecular Features and Clinical Management
Authors: McGee Rose B. , Oak Ninad , Harrison Lynn , Xu Ke , Nuccio Regina , Blake Alise K. , Mostafavi Roya , Lewis Sara , Taylor Leslie M. , Kubal Manish , Ouma Annastasia , Hines-Dowell Stacy J. , Cheng Cheng , Furtado Larissa V. , Nichols Kim E.
Published: April 2023

Supplementary Figure 1. Signature exposures in 21 samples with aoCPG variants
Supplementary Methods MS1 from Pathogenic Variants in Adult-Onset Cancer Predisposition Genes in Pediatric Cancer: Prevalence and Impact on Tumor Molecular Features and Clinical Management
Authors: McGee Rose B. , Oak Ninad , Harrison Lynn , Xu Ke , Nuccio Regina , Blake Alise K. , Mostafavi Roya , Lewis Sara , Taylor Leslie M. , Kubal Manish , Ouma Annastasia , Hines-Dowell Stacy J. , Cheng Cheng , Furtado Larissa V. , Nichols Kim E.
Published: April 2023

Supplementary Methods
Supplementary Data- Tables TS1-6 from Pathogenic Variants in Adult-Onset Cancer Predisposition Genes in Pediatric Cancer: Prevalence and Impact on Tumor Molecular Features and Clinical Management
Authors: McGee Rose B. , Oak Ninad , Harrison Lynn , Xu Ke , Nuccio Regina , Blake Alise K. , Mostafavi Roya , Lewis Sara , Taylor Leslie M. , Kubal Manish , Ouma Annastasia , Hines-Dowell Stacy J. , Cheng Cheng , Furtado Larissa V. , Nichols Kim E.
Published: April 2023

Supplementary Tables 1-6
Supplementary Figure S4 from Protein Kinase B (PKB/AKT) Protects IDH-Mutated Glioma from Ferroptosis via Nrf2
Authors: Liu Yang , Chou Fu-Ju , Lang Fengchao , Zhang Meili , Song Hua , Zhang Wei , Davis Dionne L. , Briceno Nicole J. , Zhang Yang , Cimino Patrick J. , Zaghloul Kareem A. , Gilbert Mark R. , Armstrong Terri S. , Yang Chunzhang
Published: April 2023

(A) Heatmap of gene expression profile for glioma specimen. The leading edge of the KEGG_MTOR_SIGNALING_PATHWAY geneset was shown. (B) Dose-response curve measured the cell viability in IDH1WT NHA cells in response to TMZ/Ipa combination treatment. (C) isobologram analysis showed the synergistic effect of TMZ and Ipa in IDH1WT NHA cells. (D) The combination index (C.I.) was calculated to show the additive effect of TMZ and Ipa.
Supplementary Figure S3 from Protein Kinase B (PKB/AKT) Protects IDH-Mutated Glioma from Ferroptosis via Nrf2
Authors: Liu Yang , Chou Fu-Ju , Lang Fengchao , Zhang Meili , Song Hua , Zhang Wei , Davis Dionne L. , Briceno Nicole J. , Zhang Yang , Cimino Patrick J. , Zaghloul Kareem A. , Gilbert Mark R. , Armstrong Terri S. , Yang Chunzhang
Published: April 2023

(A) Phase contrast images showed the cytotoxicity of TMZ (400 mM)/ipatasertib (Ipa, 2 mM) combination treatment in the brain tumor-initiating cells (BTICs). A ferroptosis inhibitor, Ferrstain-1 (Ferr-1, 5 mM), was used to rescue the ferroptotic cell death. Bar = 100 mM. (B) Representative flow cytometric analysis of live/dead staining in BTICs in response to TMZ/Ipa treatment. (C) Statistical analysis of dead/live cell ratio in BTICs. (D) The limiting dilution assay evaluated the frequency of generating spheres in GSC827 and TSC603 after receiving TMZ/Ipa treatment. **p < 0.01.
Supplementary Figure S1 from Protein Kinase B (PKB/AKT) Protects IDH-Mutated Glioma from Ferroptosis via Nrf2
Authors: Liu Yang , Chou Fu-Ju , Lang Fengchao , Zhang Meili , Song Hua , Zhang Wei , Davis Dionne L. , Briceno Nicole J. , Zhang Yang , Cimino Patrick J. , Zaghloul Kareem A. , Gilbert Mark R. , Armstrong Terri S. , Yang Chunzhang
Published: April 2023

(A) Immunoblotting analysis evaluated the siRNA knockdown efficiency of AKT in U87 cells. (B) Phase contrast imaging showed the cytotoxicity of ipatasertib (Ipa) in IDH1WT and IDH1Mut NHA cells. Bar = 100 mM. (C) Representative flow cytometric analysis of live/dead staining in IDH1WT and IDH1Mut NHA cells in response to Ipa (0, 1, and 2 mM) treatment. (D) Statistical analysis of dead/live cell ratio in IDH1WT and IDHMut NHA cells after Ipa treatment. **p < 0.01.
Figure S6 from An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas
Authors: Lu Xiaofan , Vano Yann , Helleux Alexandra , Su Xiaoping , Lindner Véronique , Davidson Guillaume , Mouawad Roger , Spano Jean-Philippe , Rouprêt Morgan , Elaidi Reza , Compérat Eva , Verkarre Virginie , Sun Chengming , Chevreau Christine , Bennamoun Mostefa , Lang Hervé , Tricard Thibault , Cheng Wenxuan , Xu Li , Davidson Irwin , Yan Fangrong , Fridman Wolf Herman , Sautes-Fridman Catherine , Oudard Stéphane , Malouf Gabriel G.
Published: April 2023

Figure S6. a) Heatmap showing the methylation profiles of two 𝑇𝐸𝐷 phenotypes by unsupervised clustering of enhancer probes in the BIONIKK cohort; samples were combined from both immunotherapy and target therapy arms. Kaplan-Meier survival curves showing the survival rate of two 𝑇𝐸𝐷 phenotypes in view of b) OS, c) PFS, and d) TST.
Figure S6 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Authors: Tucker Elizabeth R. , Jiménez Irene , Chen Lindi , Bellini Angela , Gorrini Chiara , Calton Elizabeth , Gao Qiong , Che Harvey , Poon Evon , Jamin Yann , Martins Da Costa Barbara , Barker Karen , Shrestha Sumana , Hutchinson J. Ciaran , Dhariwal Simran , Goodman Angharad , Del Nery Elaine , Gestraud Pierre , Bhalshankar Jaydutt , Iddir Yasmine , Saberi-Ansari Elnaz , Saint-Charles Alexandra , Geoerger Birgit , Marques Da Costa Maria Eugénia , Pierre-Eugène Cécile , Janoueix-Lerosey Isabelle , Decaudin Didier , Nemati Fariba , Carcaboso Angel M. , Surdez Didier , Delattre Olivier , George Sally L. , Chesler Louis , Tweddle Deborah A. , Schleiermacher Gudrun
Published: April 2023

Cell line growth curves and PDX data for idasanutlin combination
Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Authors: Tucker Elizabeth R. , Jiménez Irene , Chen Lindi , Bellini Angela , Gorrini Chiara , Calton Elizabeth , Gao Qiong , Che Harvey , Poon Evon , Jamin Yann , Martins Da Costa Barbara , Barker Karen , Shrestha Sumana , Hutchinson J. Ciaran , Dhariwal Simran , Goodman Angharad , Del Nery Elaine , Gestraud Pierre , Bhalshankar Jaydutt , Iddir Yasmine , Saberi-Ansari Elnaz , Saint-Charles Alexandra , Geoerger Birgit , Marques Da Costa Maria Eugénia , Pierre-Eugène Cécile , Janoueix-Lerosey Isabelle , Decaudin Didier , Nemati Fariba , Carcaboso Angel M. , Surdez Didier , Delattre Olivier , George Sally L. , Chesler Louis , Tweddle Deborah A. , Schleiermacher Gudrun
Published: April 2023

PDX data and clinical data
Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
Authors: Tucker Elizabeth R. , Jiménez Irene , Chen Lindi , Bellini Angela , Gorrini Chiara , Calton Elizabeth , Gao Qiong , Che Harvey , Poon Evon , Jamin Yann , Martins Da Costa Barbara , Barker Karen , Shrestha Sumana , Hutchinson J. Ciaran , Dhariwal Simran , Goodman Angharad , Del Nery Elaine , Gestraud Pierre , Bhalshankar Jaydutt , Iddir Yasmine , Saberi-Ansari Elnaz , Saint-Charles Alexandra , Geoerger Birgit , Marques Da Costa Maria Eugénia , Pierre-Eugène Cécile , Janoueix-Lerosey Isabelle , Decaudin Didier , Nemati Fariba , Carcaboso Angel M. , Surdez Didier , Delattre Olivier , George Sally L. , Chesler Louis , Tweddle Deborah A. , Schleiermacher Gudrun
Published: April 2023

Cell line and PDX genetics
Supplementary table 4 from Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma
Authors: Tobin Richard P. , Cogswell Dasha T. , Cates Victoria M. , Davis Dana M. , Borgers Jessica S.W. , Van Gulick Robert J. , Katsnelson Elizabeth , Couts Kasey L. , Jordan Kimberly R. , Gao Dexiang , Davila Eduardo , Medina Theresa M. , Lewis Karl D. , Gonzalez Rene , McFarland Ross W. , Robinson William A. , McCarter Martin D.
Published: April 2023

Characteristics of patients experiencing clinical benefit
Supplementary Figure S2 from Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma
Authors: Tobin Richard P. , Cogswell Dasha T. , Cates Victoria M. , Davis Dana M. , Borgers Jessica S.W. , Van Gulick Robert J. , Katsnelson Elizabeth , Couts Kasey L. , Jordan Kimberly R. , Gao Dexiang , Davila Eduardo , Medina Theresa M. , Lewis Karl D. , Gonzalez Rene , McFarland Ross W. , Robinson William A. , McCarter Martin D.
Published: April 2023

Supplementary figure 2. Changes in other clinical hematologic measures. Colored box denotes the time when the patients were being treated with ATRA. * Denotes p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Supplementary Figure S1 from Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma
Authors: Tobin Richard P. , Cogswell Dasha T. , Cates Victoria M. , Davis Dana M. , Borgers Jessica S.W. , Van Gulick Robert J. , Katsnelson Elizabeth , Couts Kasey L. , Jordan Kimberly R. , Gao Dexiang , Davila Eduardo , Medina Theresa M. , Lewis Karl D. , Gonzalez Rene , McFarland Ross W. , Robinson William A. , McCarter Martin D.
Published: April 2023

Supplementary figure 1. (A) Changes in other circulating cytokines. Colored box denotes the time when the patients were being treated with ATRA. (B) example gating strategy for CD8+ T cell activation.
Supplementary Information 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
Authors: Orzan Francesca , De Bacco Francesca , Lazzarini Elisabetta , Crisafulli Giovanni , Gasparini Alessandra , Dipasquale Angelo , Barault Ludovic , Macagno Marco , Persico Pasquale , Pessina Federico , Bono Beatrice , Giordano Laura , Zeppa Pietro , Melcarne Antonio , Cassoni Paola , Garbossa Diego , Santoro Armando , Comoglio Paolo M. , Indraccolo Stefano , Simonelli Matteo , Boccaccio Carla
Published: April 2023

Supplementary Figures 1-4, Supplementary Tables S1-S13, Description of Supplementary Data 1-3, Supplementary Materials and Methods, Supplementary References.
Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
Authors: Orzan Francesca , De Bacco Francesca , Lazzarini Elisabetta , Crisafulli Giovanni , Gasparini Alessandra , Dipasquale Angelo , Barault Ludovic , Macagno Marco , Persico Pasquale , Pessina Federico , Bono Beatrice , Giordano Laura , Zeppa Pietro , Melcarne Antonio , Cassoni Paola , Garbossa Diego , Santoro Armando , Comoglio Paolo M. , Indraccolo Stefano , Simonelli Matteo , Boccaccio Carla
Published: April 2023

Primers and probes.
Supplementary Tables S3-S13 from Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma
Authors: Vasudev Naveen S. , Scelo Ghislaine , Glennon Kate I. , Wilson Michelle , Letourneau Louis , Eveleigh Robert , Nourbehesht Nazanin , Arseneault Madeleine , Paccard Antoine , Egevad Lars , Viksna Juris , Celms Edgars , Jackson Sharon M. , Abedi-Ardekani Behnoush , Warren Anne Y. , Selby Peter J. , Trainor Sebastian , Kimuli Michael , Cartledge Jon , Soomro Naeem , Adeyoju Adebanji , Patel Poulam M. , Wozniak Magdalena B. , Holcatova Ivana , Brisuda Antonin , Janout Vladimir , Chanudet Estelle , Zaridze David , Moukeria Anush , Shangina Oxana , Foretova Lenka , Navratilova Marie , Mates Dana , Jinga Viorel , Bogdanovic Ljiljana , Kovacevic Bozidar , Cambon-Thomsen Anne , Bourque Guillaume , Brazma Alvis , Tost Jörg , Brennan Paul , Lathrop Mark , Riazalhosseini Yasser , Banks Rosamonde E.
Published: April 2023

Supplementary Tables S3-S13
Figure S2 from Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma
Authors: Vasudev Naveen S. , Scelo Ghislaine , Glennon Kate I. , Wilson Michelle , Letourneau Louis , Eveleigh Robert , Nourbehesht Nazanin , Arseneault Madeleine , Paccard Antoine , Egevad Lars , Viksna Juris , Celms Edgars , Jackson Sharon M. , Abedi-Ardekani Behnoush , Warren Anne Y. , Selby Peter J. , Trainor Sebastian , Kimuli Michael , Cartledge Jon , Soomro Naeem , Adeyoju Adebanji , Patel Poulam M. , Wozniak Magdalena B. , Holcatova Ivana , Brisuda Antonin , Janout Vladimir , Chanudet Estelle , Zaridze David , Moukeria Anush , Shangina Oxana , Foretova Lenka , Navratilova Marie , Mates Dana , Jinga Viorel , Bogdanovic Ljiljana , Kovacevic Bozidar , Cambon-Thomsen Anne , Bourque Guillaume , Brazma Alvis , Tost Jörg , Brennan Paul , Lathrop Mark , Riazalhosseini Yasser , Banks Rosamonde E.
Published: April 2023

DFS amongst Leibovich risk groups stratified by genomic classifier
Figure S1 from Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma
Authors: Vasudev Naveen S. , Scelo Ghislaine , Glennon Kate I. , Wilson Michelle , Letourneau Louis , Eveleigh Robert , Nourbehesht Nazanin , Arseneault Madeleine , Paccard Antoine , Egevad Lars , Viksna Juris , Celms Edgars , Jackson Sharon M. , Abedi-Ardekani Behnoush , Warren Anne Y. , Selby Peter J. , Trainor Sebastian , Kimuli Michael , Cartledge Jon , Soomro Naeem , Adeyoju Adebanji , Patel Poulam M. , Wozniak Magdalena B. , Holcatova Ivana , Brisuda Antonin , Janout Vladimir , Chanudet Estelle , Zaridze David , Moukeria Anush , Shangina Oxana , Foretova Lenka , Navratilova Marie , Mates Dana , Jinga Viorel , Bogdanovic Ljiljana , Kovacevic Bozidar , Cambon-Thomsen Anne , Bourque Guillaume , Brazma Alvis , Tost Jörg , Brennan Paul , Lathrop Mark , Riazalhosseini Yasser , Banks Rosamonde E.
Published: April 2023

Disease-Free Survival outcomes amongst genomic groups when applied to the 247 VHL mutated ccRCCs from the TCGA dataset
Figure S8 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
Authors: Chopra Shalini , Trepka Kai , Sakhamuri Sasank , Carretero-González Alberto , Zhu Jun , Egusa Emily , Zhou Jie , Leung Kevin , Zhao Ning , Hooshdaran Nima , Feng Felix Y. , Wells James A. , Chou Jonathan , Evans Michael J.
Published: April 2023

CDCP1 mRNA is not correlated NECTIN4 or TROP2 mRNA, related to Figure 2C. Spearman correlation analyses were performed between CDCP1 and NECTIN4 or TROP2 for the Seiler, Sjodahl 2017, and Sjodahl 2012 datasets, with p values and correlation coefficients shown. Points are colored by consensus subtype as in Figure 1.
Figure S6 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
Authors: Chopra Shalini , Trepka Kai , Sakhamuri Sasank , Carretero-González Alberto , Zhu Jun , Egusa Emily , Zhou Jie , Leung Kevin , Zhao Ning , Hooshdaran Nima , Feng Felix Y. , Wells James A. , Chou Jonathan , Evans Michael J.
Published: April 2023

CDCP1 mRNA expression is not associated with overall survival. Kaplan–Meier survival analyses were performed on quartiles of CDCP1 mRNA expression with overall survival as the endpoint. p > 0.05 in both public datasets for which overall survival data were available.
Figure S3 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
Authors: Chopra Shalini , Trepka Kai , Sakhamuri Sasank , Carretero-González Alberto , Zhu Jun , Egusa Emily , Zhou Jie , Leung Kevin , Zhao Ning , Hooshdaran Nima , Feng Felix Y. , Wells James A. , Chou Jonathan , Evans Michael J.
Published: April 2023

CDCP1 protein expression by clinical stage using the tissue microarray. p=0.32 by Kruskal-Wallis test.
Figure S10 from Theranostic Targeting of CUB Domain–Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer
Authors: Chopra Shalini , Trepka Kai , Sakhamuri Sasank , Carretero-González Alberto , Zhu Jun , Egusa Emily , Zhou Jie , Leung Kevin , Zhao Ning , Hooshdaran Nima , Feng Felix Y. , Wells James A. , Chou Jonathan , Evans Michael J.
Published: April 2023

A plot showing the mean tumor volume for the vehicle and treated arms from the antitumor assessment study in mice bearing UMUC3 xenografts. The differences in mean between treatment arms was found to be significant (P < 0.001) using an unpaired, two tailed t test by day 20. Data are reported as mean ± standard deviation.
Data from Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma
Authors: Tobin Richard P. , Cogswell Dasha T. , Cates Victoria M. , Davis Dana M. , Borgers Jessica S.W. , Van Gulick Robert J. , Katsnelson Elizabeth , Couts Kasey L. , Jordan Kimberly R. , Gao Dexiang , Davila Eduardo , Medina Theresa M. , Lewis Karl D. , Gonzalez Rene , McFarland Ross W. , Robinson William A. , McCarter Martin D.
Published: April 2023

AbstractPurpose:
A phase Ib/II clinical trial was conducted to evaluate the safety and efficacy of the combination of all-trans retinoic acid (ATRA) with pembrolizumab in patients with stage IV melanoma.
Patients and Methods:
Anti–PD-1 naïve patients with stage IV melanoma were treated with pembrolizumab plus supplemental ATRA for three days surrounding each of the first four pembrolizumab infusions. The primary objective was to establish the MTD and recommended phase II dose (RP2D) of the combination. The secondary objectives were to describe the safety and toxicity of the combined treatment and to assess antitumor activity in terms of (i) the reduction in circulating myeloid-derived suppressor cell (MDSC) frequency and (ii) progression-free survival (PFS).
Results:
Twenty-four patients were enrolled, 46% diagnosed with M1a and 29% with M1c stage disease at enrollment. All patients had an ECOG status ≤1, and 75% had received no prior therapies. The combination was well tolerated, with the most common ATRA-related adverse events being headache, fatigue, and nausea. The RP2D was established at 150 mg/m2 ATRA + 200 mg Q3W pembrolizumab. Median PFS was 20.3 months, and the overall response rate was 71%, with 50% of patients experiencing a complete response, and the 1-year overall survival was 80%. The combination effectively lowered the frequency of circulating MDSCs.
Conclusions:
With a favorable tolerability and high response rate, this combination is a promising frontline treatment strategy for advanced melanoma. Targeting MDSCs remains an attractive mechanism to enhance the efficacy of immunotherapies, and this combination merits further investigation.

See related commentary by Olson and Luke, p. 1167
Supplementary Figure Legends and Supplementary Table 1 from Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
Authors: Yap Timothy A. , Walton Mike I. , Hunter Lisa-Jane K. , Valenti Melanie , de Haven Brandon Alexis , Eve Paul D. , Ruddle Ruth , Heaton Simon P. , Henley Alan , Pickard Lisa , Vijayaraghavan Gowri , Caldwell John J. , Thompson Neil T. , Aherne Wynne , Raynaud Florence I. , Eccles Suzanne A. , Workman Paul , Collins Ian , Garrett Michelle D.
Published: April 2023

Supplementary Figure Legends and Supplementary Table 1 from Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
Supplementary Figure 3 from Loss of the Malignant Phenotype of Human Neuroblastoma Cells by a Catalytically Inactive Dominant-Negative hTERT Mutant
Authors: Samy Mona , Gattolliat Charles-Henry , Pendino Frédéric , Hillion Josette , Nguyen Eric , Bombard Sophie , Douc-Rasy Sétha , Bénard Jean , Ségal-Bendirdjian Evelyne
Published: April 2023

PDF file, 84K, Loss of the mutant P53 alleles during the culture expansion of the DN-hTERT transduced IGR-N-91 cells.
Supplementary Figure 2 from Loss of the Malignant Phenotype of Human Neuroblastoma Cells by a Catalytically Inactive Dominant-Negative hTERT Mutant
Authors: Samy Mona , Gattolliat Charles-Henry , Pendino Frédéric , Hillion Josette , Nguyen Eric , Bombard Sophie , Douc-Rasy Sétha , Bénard Jean , Ségal-Bendirdjian Evelyne
Published: April 2023

PDF file, 38K, hTERT expression and activity in WT-hTERT transduced cells.
Supplementary Figure Legend from Proteasome Inhibition Blocks NF-κB and ERK1/2 Pathways, Restores Antigen Expression, and Sensitizes Resistant Human Melanoma to TCR-Engineered CTLs
Authors: Jazirehi Ali R. , Economou James S.
Published: April 2023

PDF file, 55KB.
Supplementary Figure 1 from Loss of the Malignant Phenotype of Human Neuroblastoma Cells by a Catalytically Inactive Dominant-Negative hTERT Mutant
Authors: Samy Mona , Gattolliat Charles-Henry , Pendino Frédéric , Hillion Josette , Nguyen Eric , Bombard Sophie , Douc-Rasy Sétha , Bénard Jean , Ségal-Bendirdjian Evelyne
Published: April 2023

PDF file, 41K, Loss of DN-hTERT sequence of the transgene during the culture expansion of the transduced IGR-N-91 cells.
Supplementary Figure Legends 1-3 from The Multitargeted Receptor Tyrosine Kinase Inhibitor Linifanib (ABT-869) Induces Apoptosis through an Akt and Glycogen Synthase Kinase 3β–Dependent Pathway
Authors: Hernandez-Davies Jenny E. , Zape Joan P. , Landaw Elliot M. , Tan Xiaolin , Presnell Ajia , Griffith Diana , Heinrich Michael C. , Glaser Keith B. , Sakamoto Kathleen M.
Published: April 2023

Supplementary Figure Legends 1-3 from The Multitargeted Receptor Tyrosine Kinase Inhibitor Linifanib (ABT-869) Induces Apoptosis through an Akt and Glycogen Synthase Kinase 3β–Dependent Pathway
Supplementary Figure 2 from The Multitargeted Receptor Tyrosine Kinase Inhibitor Linifanib (ABT-869) Induces Apoptosis through an Akt and Glycogen Synthase Kinase 3β–Dependent Pathway
Authors: Hernandez-Davies Jenny E. , Zape Joan P. , Landaw Elliot M. , Tan Xiaolin , Presnell Ajia , Griffith Diana , Heinrich Michael C. , Glaser Keith B. , Sakamoto Kathleen M.
Published: April 2023

Supplementary Figure 2 from The Multitargeted Receptor Tyrosine Kinase Inhibitor Linifanib (ABT-869) Induces Apoptosis through an Akt and Glycogen Synthase Kinase 3β–Dependent Pathway
Supplementary Figure 3 from Inhibition of SAPK2/p38 Enhances Sensitivity to mTORC1 Inhibition by Blocking IRES-Mediated Translation Initiation in Glioblastoma
Authors: Cloninger Cheri , Bernath Andrew , Bashir Tariq , Holmes Brent , Artinian Nicholas , Ruegg Teresa , Anderson Lauren , Masri Janine , Lichtenstein Alan , Gera Joseph
Published: April 2023

PDF file - 520K
Supplementary Figure 2 from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Authors: Rivera Victor M. , Squillace Rachel M. , Miller David , Berk Lori , Wardwell Scott D. , Ning Yaoyu , Pollock Roy , Narasimhan Narayana I. , Iuliucci John D. , Wang Frank , Clackson Tim
Published: April 2023

Supplementary Figure 2 from Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
Supplementary Figures 1-2 from Studies on Mechanism of Action of Anticancer Peptides by Modulation of Hydrophobicity Within a Defined Structural Framework
Authors: Huang Yi-bing , Wang Xiao-fei , Wang Hong-ye , Liu Yu , Chen Yuxin
Published: April 2023

Supplementary Figures 1-2 from Studies on Mechanism of Action of Anticancer Peptides by Modulation of Hydrophobicity Within a Defined Structural Framework
Supplementary Figures 1-3 from CBP501-Calmodulin Binding Contributes to Sensitizing Tumor Cells to Cisplatin and Bleomycin
Authors: Mine Naoki , Yamamoto Sayaka , Saito Naoya , Yamazaki Satoshi , Suda Chikako , Ishigaki Machiyo , Kufe Donald W. , Von Hoff Daniel D. , Kawabe Takumi
Published: April 2023

PDF file -62K
Supplementary Figure 3 from Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
Authors: Lund Per , Kotova Irina , Kedinger Valérie , Khanwalkar Harshal , Voltz Emilie , Hahn William C. , Gronemeyer Hinrich
Published: April 2023

Supplementary Figure 3 from Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
Supplementary Figure 2 from Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
Authors: Lund Per , Kotova Irina , Kedinger Valérie , Khanwalkar Harshal , Voltz Emilie , Hahn William C. , Gronemeyer Hinrich
Published: April 2023

Supplementary Figure 2 from Transformation-Dependent Silencing of Tumor-Selective Apoptosis-Inducing TRAIL by DNA Hypermethylation Is Antagonized by Decitabine
Supplementary Materials and Methods, Tables 1-2 from Tasisulam Sodium, an Antitumor Agent That Inhibits Mitotic Progression and Induces Vascular Normalization
Authors: Meier Timothy , Uhlik Mark , Chintharlapalli Sudhakar , Dowless Michele , Van Horn Robert , Stewart Julie , Blosser Wayne , Cook James , Young Debra , Ye Xiang , Evans Glenn , Credille Kelly , Ballard Darryl , Huber Lysiane , Capen Andrew , Chedid Marcio , Ilaria Robert , Smith Michele C. , Stancato Louis
Published: April 2023

PDF - 82K
Supplementary Figure 4 from Inhibition of OCTN2-Mediated Transport of Carnitine by Etoposide
Authors: Hu Chaoxin , Lancaster Cynthia S. , Zuo Zhili , Hu Shuiying , Chen Zhaoyuan , Rubnitz Jeffrey E. , Baker Sharyn D. , Sparreboom Alex
Published: April 2023

PDF file - 172K
Supplementary Figure 4 from Tasisulam Sodium, an Antitumor Agent That Inhibits Mitotic Progression and Induces Vascular Normalization
Authors: Meier Timothy , Uhlik Mark , Chintharlapalli Sudhakar , Dowless Michele , Van Horn Robert , Stewart Julie , Blosser Wayne , Cook James , Young Debra , Ye Xiang , Evans Glenn , Credille Kelly , Ballard Darryl , Huber Lysiane , Capen Andrew , Chedid Marcio , Ilaria Robert , Smith Michele C. , Stancato Louis
Published: April 2023

PDF file - 355K
Supplementary Figure 2 from Inhibition of OCTN2-Mediated Transport of Carnitine by Etoposide
Authors: Hu Chaoxin , Lancaster Cynthia S. , Zuo Zhili , Hu Shuiying , Chen Zhaoyuan , Rubnitz Jeffrey E. , Baker Sharyn D. , Sparreboom Alex
Published: April 2023

PDF file - 107K
Supplementary Figure 3 from Tasisulam Sodium, an Antitumor Agent That Inhibits Mitotic Progression and Induces Vascular Normalization
Authors: Meier Timothy , Uhlik Mark , Chintharlapalli Sudhakar , Dowless Michele , Van Horn Robert , Stewart Julie , Blosser Wayne , Cook James , Young Debra , Ye Xiang , Evans Glenn , Credille Kelly , Ballard Darryl , Huber Lysiane , Capen Andrew , Chedid Marcio , Ilaria Robert , Smith Michele C. , Stancato Louis
Published: April 2023

PDF file - 400K
Supplementary Figure 2 from Tasisulam Sodium, an Antitumor Agent That Inhibits Mitotic Progression and Induces Vascular Normalization
Authors: Meier Timothy , Uhlik Mark , Chintharlapalli Sudhakar , Dowless Michele , Van Horn Robert , Stewart Julie , Blosser Wayne , Cook James , Young Debra , Ye Xiang , Evans Glenn , Credille Kelly , Ballard Darryl , Huber Lysiane , Capen Andrew , Chedid Marcio , Ilaria Robert , Smith Michele C. , Stancato Louis
Published: April 2023

PDF file - 1.3MB
Supplementary Figures 1-4 from Therapeutic Significance of Estrogen Receptor β Agonists in Gliomas
Authors: Sareddy Gangadhara R. , Nair Binoj C. , Gonugunta Vijay K. , Zhang Quan-guang , Brenner Andrew , Brann Darrell W. , Tekmal Rajeshwar Rao , Vadlamudi Ratna K.
Published: April 2023

PDF file - 177K, Specificity of ER beta reagents
Supplementary Figure 1 from Cell Intrinsic Role of COX-2 in Pancreatic Cancer Development
Authors: Hill Reginald , Li Yunfeng , Tran Linh M. , Dry Sarah , Calvopina Joseph Hargan , Garcia Alejandro , Kim Christine , Wang Ying , Donahue Timothy R. , Herschman Harvey R. , Wu Hong
Published: April 2023

PDF file, 275K, GRP78 expression in human and mouse PDAC.
Supplementary Figure 1 from Targeting the Mitochondria Activates Two Independent Cell Death Pathways in Ovarian Cancer Stem Cells
Authors: Alvero Ayesha B. , Montagna Michele K. , Holmberg Jennie C. , Craveiro Vinicius , Brown David , Mor Gil
Published: April 2023

Supplementary Figure 1 from Targeting the Mitochondria Activates Two Independent Cell Death Pathways in Ovarian Cancer Stem Cells
Supplementary Figures 1-3 from CYP2S1 and CYP2W1 Mediate 2-(3,4-Dimethoxyphenyl)-5-Fluorobenzothiazole (GW-610, NSC 721648) Sensitivity in Breast and Colorectal Cancer Cells
Authors: Tan Boon Shing , Tiong Kai Hung , Muruhadas Ashwin , Randhawa Nirmal , Choo Heng Lungh , Bradshaw Tracey D. , Stevens Malcolm F.G. , Leong Chee-Onn
Published: April 2023

PDF file - 569K
Supplementary Table 1 from REST Is a Novel Prognostic Factor and Therapeutic Target for Medulloblastoma
Authors: Taylor Pete , Fangusaro Jason , Rajaram Veena , Goldman Stewart , Helenowski Irene B. , MacDonald Tobey , Hasselblatt Martin , Riedemann Lars , Laureano Alvaro , Cooper Laurence , Gopalakrishnan Vidya
Published: April 2023

PDF file, 338KB, Table1A. Overview of Database; Table 1B. Event Free Survival (EFS); Table 1C. Overall Survival (OS).
Supplementary Table 1 from Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide
Authors: Yo Yi-Te , Lin Ya-Wen , Wang Yu-Chi , Balch Curt , Huang Rui-Lan , Chan Michael W.Y. , Sytwu Huey-Kang , Chen Chi-Kuan , Chang Cheng-Chang , Nephew Kenneth P. , Huang Tim , Yu Mu-Hsien , Lai Hung-Cheng
Published: April 2023

PDF file, 27KB, Differential stem cell signaling between CP70 and CP70sps were compared using an RT-PCR pathway-focused arrays (Stem signaling/Wnt signaling). Red indicates gene upregulation while green indicates gene downregulation, in CP70sps cells. Numbers indicate fold changes. Table S1A is a general focus array containing genes in Wnt, Notch, Hedgehog signaling pathways. Table S1B is a focus array on Wnt signaling.
Supplementary Figure Legend from Genetic Variation That Predicts Platinum Sensitivity Reveals the Role of miR-193b* in Chemotherapeutic Susceptibility
Authors: Ziliak Dana , Gamazon Eric R. , LaCroix Bonnie , Kyung Im Hae , Wen Yujia , Huang Rong Stephanie
Published: April 2023

PDF file, 57K.
Supplementary Figure 1 from The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates
Authors: Erickson Hans K. , Lewis Phillips Gail D. , Leipold Douglas D. , Provenzano Carmela A. , Mai Elaine , Johnson Holly A. , Gunter Bert , Audette Charlene A. , Gupta Manish , Pinkas Jan , Tibbitts Jay
Published: April 2023

PDF file - 133K, Target cell catabolism of T-DM1 and T-SPP-DM1 in the HER2-positive breast carcinoma cells SK-BR-3 and MCF7-neo/HER2.
Supplementary Figure 5 from High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non–Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway
Authors: Levallet Guénaëlle , Bergot Emmanuel , Antoine Martine , Creveuil Christian , Santos Adriana O. , Beau-Faller Michelle , de Fraipont Florence , Brambilla Elisabeth , Levallet Jérôme , Morin Franck , Westeel Virginie , Wislez Marie , Quoix Elisabeth , Debieuvre Didier , Dubois Fatéméh , Rouquette Isabelle , Pujol Jean-Louis , Moro-Sibilot Denis , Camonis Jacques , Zalcman Gérard
Published: April 2023

PDF file - 252K, TUBB3 protein expression in HBEC cells is reduced by hypoxia cells culture conditions
Supplementary Table 2 from Activity of a Py–Im Polyamide Targeted to the Estrogen Response Element
Authors: Nickols Nicholas G. , Szablowski Jerzy O. , Hargrove Amanda E. , Li Benjamin C. , Raskatov Jevgenij A. , Dervan Peter B.
Published: April 2023

PDF File - 31K, Table of genes whose induction (or repression) by E2 is inhibited (or re-repressed) by 1 in RNA-seq.
Supplementary Movie 2 from O(6)-Methylguanine-DNA Methyltransferase Is a Novel Negative Effector of Invasion in Glioblastoma Multiforme
Authors: Chahal Manik , Abdulkarim Bassam , Xu Yaoxian , Guiot Marie-Christine , Easaw Jacob C. , Stifani Nicolas , Sabri Siham
Published: April 2023

MP4 file - 542K, Motility of U87/MGMT cells
Supplementary Movie 1 from O(6)-Methylguanine-DNA Methyltransferase Is a Novel Negative Effector of Invasion in Glioblastoma Multiforme
Authors: Chahal Manik , Abdulkarim Bassam , Xu Yaoxian , Guiot Marie-Christine , Easaw Jacob C. , Stifani Nicolas , Sabri Siham
Published: April 2023

MP4 file - 789K, Motility of U87/EV cells
Supplementary Figure 2 from O(6)-Methylguanine-DNA Methyltransferase Is a Novel Negative Effector of Invasion in Glioblastoma Multiforme
Authors: Chahal Manik , Abdulkarim Bassam , Xu Yaoxian , Guiot Marie-Christine , Easaw Jacob C. , Stifani Nicolas , Sabri Siham
Published: April 2023

PDF file - 5765K, Morphology of MGMT-knockdown and depleted cells
Supplementary Figures from Histone Deacetylase Inhibition Overcomes Drug Resistance through a miRNA-Dependent Mechanism
Authors: Murray-Stewart Tracy , Hanigan Christin L. , Woster Patrick M. , Marton Laurence J. , Casero Robert A.
Published: April 2023

PDF file, 87K, Figure S1. Chemical structures of the natural polyamine spermine and the spermine analogues PG-11047 and BENSpm. Figure S2. Effects of treatment with PG-11047, BENSpm, and MS-275 on chromatin acetylation status. (A) Promoter region occupancy of the SSAT gene of H82 cells by AcH3K9 with or without 48-hour combination treatments was assayed by ChIP. (B) SSAT promoter region occupancy of Calu-6 cells by AcH3K9 following 24-h co-treatments was assayed by ChIP. Immunoprecipitation with an antibody to total H3 was used as reference for quantification. The change in occupancy at each locus was determined by qPCR and presented as fold enrichment relative to untreated cells. Results are the means of three independent determinations, with error bars indicating standard error.
Supplementary Methods and Figure Legends from Crizotinib Induces PUMA-Dependent Apoptosis in Colon Cancer Cells
Authors: Zheng Xingnan , He Kan , Zhang Lin , Yu Jian
Published: April 2023

PDF file - 139 KB
Supplementary Figures 1-7 from VS-5584, a Novel and Highly Selective PI3K/mTOR Kinase Inhibitor for the Treatment of Cancer
Authors: Hart Stefan , Novotny-Diermayr Veronica , Goh Kee Chuan , Williams Meredith , Tan Yong Cheng , Ong Lai Chun , Cheong Albert , Ng Bee Kheng , Amalini Chithra , Madan Babita , Nagaraj Harish , Jayaraman Ramesh , Pasha Khalid M. , Ethirajulu Kantharaj , Chng Wee Joo , Mustafa Nurulhuda , Goh Boon Cher , Benes Cyril , McDermott Ultan , Garnett Mathew , Dymock Brian , Wood Jeanette M.
Published: April 2023

PDF file - 663K, Ambit kinome tree, Cell proliferation data, Pharmacokinetics, Body weight changes in PC3 efficacy study, Active vessel stain in COLO-205 efficacy study, MV4-11 efficacy model, Drug sensitivity profiling and correlation to mutation status
Supplementary Figure 1 from Targeting CXCR2 Enhances Chemotherapeutic Response, Inhibits Mammary Tumor Growth, Angiogenesis, and Lung Metastasis
Authors: Sharma Bhawna , Nawandar Dhananjay M. , Nannuru Kalyan C. , Varney Michelle L. , Singh Rakesh K.
Published: April 2023

PDF file - 54K, Figure S1: Percentage inhibition in SKBR3 control and SKBR3 CXCR2 over-expressing cells (SKBR3 CXCR2) by doxorubicin and paclitaxel evaluated by MTT assay. We observed a decrease in the percentage inhibition of SKBR3 cells over-expressing CXCR2 receptor after doxorubicin and paclitaxel treatment in comparison to control cells suggesting CXCR2 over-expression make breast cancer cells resistant to chemotherapy. We also noticed that CXCR2 expression has effect at lower concentrations of the drugs consistent with our CXCR2 knockdown studies.
Supplementary Figure 1 from Epithelial Tissue Hyperplasia Induced by the RAF Inhibitor PF-04880594 Is Attenuated by a Clinically Well-Tolerated Dose of the MEK Inhibitor PD-0325901
Authors: Torti Vince R. , Wojciechowicz Donald , Hu Wenyue , John-Baptiste Annette , Evering Winston , Troche Gabriel , Marroquin Lisa D. , Smeal Tod , Yamazaki Shinji , Palmer Cynthia L. , Burns-Naas Leigh Ann , Bagrodia Shubha
Published: April 2023

PDF file, 39K, Relationship between oral doses and average plasma concentrations of PD-0325901 in athymic nu/nu mice.
Supplementary Table 6 from Gene Expression Profile in Response to Doxorubicin–Rapamycin Combined Treatment of HER-2–Overexpressing Human Mammary Epithelial Cell Lines
Authors: Trapé Adriana Priscila , Katayama Maria Lucia Hirata , Roela Rosimeire Aparecida , Brentani Helena , Ravacci Graziela Rosa , de Araujo Lima Leandro , Brentani Maria Mitzi
Published: April 2023

PDF file - 61K